| Ytd | -18.40% | |
| 1y | -46.48% |
| Open | 6.90 | Prev Close | 6.96 | Low | 6.67 | High | 6.96 | Mkt Cap | 456.65M |
| Vol | 405.97K | Avg Vol | 1.19M | EPS | -5.33 | P/E | N/A | Forward P/E | -1.19 |
| Beta | 1.78 | Short Ratio | 6.40 | Inst. Own | 68.36% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 8.35 | 200-d Avg | 8.34 | 1yr Est | 8.20 |
- Strengthened balance sheet with $1.8 million cash from new convertible debt in Q2 and additional $
Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting str
Prada Group CEO Andrea Guerra speaks to CNBC's Charlotte Reed about global luxury consumers, keeping
Ginkgo Bioworks NYSE: DNA reported second-quarter 2026 revenue of $20 million, down 48% from the yea
TD Cowen analyst Brendan Smith downgrades Ginkgo Bioworks Holdings (NYSE:DNA) from Buy to Hold an
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings Call Transcript
NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Fiserv, Inc. (NASDAQ: FISV), a global leader in payments
DNA Advisors brings expertise in capital markets, strategic transactions, partnerships, and growth i
CoreWeave (NASDAQ: CRWV) and Nebius Group (NASDAQ: NBIS | NBIS Price Prediction) just delivered Q1 2
Caxton Associates LLP lowered its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) by 6
Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destr
SAN FRANCISCO--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today
Taipei, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq
A new biosecurity theme is emerging, and Palantir is leveraging it as an opportunity. Here's why tha
FTAI Aviation is innovatively leveraging jet engine cores to address the urgent power needs of data
BOULDER, Colo.--(BUSINESS WIRE)-- #ArcherAnalysis--IDT's library prep solutions join Illumina's exte
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption o
New co-developed product delivers a complete Tier 1 ADME panel coupled with best-in-class AI-driven
Results provide important clinical evidence to support ApolloBio's future regulatory submission in C
Closed sale of the Company's mobile device assets to NEXA in January 2026 Completed the transfer of
Harmonic's SeaStar Optical Node Enables Cost-Effective Broadband Service Expansion in Previously Und
https://www.cdc.gov/ebola/situation-summary/index.html
Ginkgo Bioworks (DNA) reported Q1 revenues of $19.5M, down nearly 50% year-over-year and badly missi
ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transf
BTIG analyst Mark Massaro maintains Ginkgo Bioworks Holdings (NYSE:DNA) with a Sell and lowers th
Elon Musk tweeted about wanting Jurassic Park in real life. Companies aren't bringing back dinos
Ginkgo Bioworks (NYSE: DNA) today announced the official launch of Ginkgo Cloud Lab. This new interf
Ginkgo Bioworks stock drops after earnings miss, lower sales, and shift to autonomous labs and robot
Ginkgo today announced it has reached an agreement to sell the Company's biosecurity business to
Ginkgo Bioworks Holdings (NYSE:DNA) reported quarterly losses of $(1.41) per share which missed the
Ginkgo Bioworks (NYSE:DNA) today announced it has demonstrated, in collaboration with OpenAI, an AI
TD Cowen analyst Brendan Smith maintains Ginkgo Bioworks Holdings (NYSE:DNA) with a Buy and lower
Ginkgo Bioworks shares are trading higher Monday afternoon, up over 8%, following the announcement o
ProteoNic BV, a leading provider of premium vector technology for biopharmaceutical and viral vector
Ginkgo Bioworks (NYSE:DNA) today announced it has been awarded by the Environmental Molecular Scienc
Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares are trading lower on Friday. The company released its
Ginkgo Bioworks Holdings (NYSE:DNA) affirms FY2025 sales outlook from $167.000 million-$187.000 mill
Ginkgo Bioworks Holdings (NYSE:DNA) reported quarterly losses of $(1.45) per share which missed the
Ginkgo Bioworks (NYSE: DNA) announced today that it has been awarded a contract through the Biomedic
Ginkgo Bioworks (NYSE:DNA) today announced that the company has extended its multi-year strategic pa
Ginkgo Bioworks to apply its RNA construct design expertise to develop long-lived, tissue-specific,